Switching Outpatients With Bipolar or Schizoaffective Disorders and Substance Abuse From Their Current Antipsychotic to Aripiprazole
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Substance abuse is extremely common in patients with bipolar disorders, although minimal data are available on the treatment of this important clinical population. Aripiprazole is an atypical antipsychotic that is approved for the treatment of mania and that has a novel mechanism of action, acting as a dopamine-2 receptor partial agonist, thereby increasing dopamine release in some parts of the brain and decreasing dopa-mine release in other brain regions. Dopamine release is implicated in substance use, and both dopaminergic agonists and antagonists have been examined for the treatment of substance abuse. To our knowledge, dopa-mine receptor partial agonists have not been investigated for treatment of substance abuse in humans. METHOD: Twenty antipsychotic-treated patients with bipolar or schizoaffective disorder and current substance abuse were switched to open-label aripipra-zole using an overlap and taper method. At baseline, diagnoses were confirmed using the Mini-International Neuropsychiatric Interview based on DSM-IV criteria. Psychiatric symptoms, side effects, and substance use and craving were assessed over 12 weeks. Psychiatric symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Brief Psychiatric Rating Scale (BPRS). Substance craving was assessed with visual analogue scales, and side effects were monitored using the Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Barnes Akathisia Scale, and patient report. Study enrollment was from April 2003 to February 2004. RESULTS: Significant baseline-to-exit improvement in HAM-D (p = .002), YMRS (p = .021), and BPRS (p = .000) scores were observed without a significant change in antipsychotic-induced side effect scales. In 17 participants with current alcohol dependence, significant reductions in dollars spent on alcohol (p = .042) and alcohol craving (p = .003) were found. In 9 participants with cocaine-related disorders, significant reductions in cocaine craving (p = .014), but not use, were found. CONCLUSION: A change to aripiprazole was associated with symptomatic improvement. Limitations of the study include a small sample size, high attrition, and an open-label design. Controlled trials in dual-diagnosis patients are needed to confirm these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aripiprazole has level 4 evidence to decrease craving of alcohol, but not consumption, and level 4 evidence to decrease cocaine use in polysubstance users.719”
Citations
Cited by
Items 101–117 of 117
Effectiveness of aripiprazole for medication overuse headache: A case report
Yamada, K., Makihara, Y., & Imamura, Y. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02194.x · Cited by 1
The clinical challenge of comorbid bipolar disorder and substance use disorder
Salloum, I. M. (2006) · The Psychiatric times · Cited by 1
Is Aripiprazole Useful to Refrain From Cocaine Use After Detoxification (Avoiding Relapses)?
Cassano, G. B., Lattanzi, L., Litta, A., Lombardi, V., Tatulli, A., Benedetti, A., Longobardi, A., & Maremmani, I. (2009) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318195001f · Cited by 2
Atypical Antipsychotic Drugs in Dual Diagnosis Patients: A Review
Marín, M. (2015) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/2/1/1026 · Cited by 1
“(2005) [70] n=20 OL study 12 weeks BD (n=19) or SAD (n=1) + AD (n=17) and/or COUD (n=9) ARI (up to 30mg/d) Psychiatric symptoms (YMRS, HDRS, BPRS) Substance craving (VAS) Substance use (days of use/week, money spent on substances/week and UTS) ARI was associated with significant improvements in psychiatric symptoms (p…”
BackgroundFlórez, J. F. G., & Salazar, D. A. R. (2009) · Revista Colombiana de Psiquiatría · Cited by 8
Pharmacotherapy of Bipolar I Disorder: Focus on Aripiprazole
Bastiaens, L. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2238
Substance use disorders in bipolar disorder: An update
Cerullo, M. A., & Strakowski, S. M. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629392
“Aripiprazole may be effective in treating the affective symptoms in bipolar patients with comorbid SUDs and valproate (as an adjunct to lithium) and aripiprazole may help treat SUDs in bipolar patients [24, 25 ].”
BackgroundInfluentialNovel Pharmacological Treatment Alternatives for Nicotine Dependence
Lindblom, N. (2005) · Figshare
Antipsychotics Management in Addictive Disorders
Geoffroy, P. A., Rolland, B., Laprévote, V., & Cottencin, O. (2013) · Current Psychopharmacologye · doi:10.2174/221155601130200006
“Likewise, switching the antipsychotic medication to aripiprazole resulted in a significant reduction in alcohol consumption and cocaine intake in patients with bipolar or schizoaffective disorders [51].”
BackgroundSani, G., Simonetti, A., Serra, G., Solfanelli, A., Girardi, N., Janiri, D., Danese, E., Rapinesi, C., Tatarelli, R., & Girardi, P. (2016)
Assessing and Treating Co-occurring Mental Illness
Jones, M. M., & Fireman, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-29863-4_16
“Aripiprazole , an atypical psychotic with a novel mechanism of action as a dopamine2 receptor partial agonist, was found to have associated symptomatic improvement when patients were switched to it from other medication regimens [ 30 ].”
BackgroundPreuss, U. W., Wong, W. M., & Farren, C. K. (2014)
Bipolar Disorder With Comorbid Alcohol or Substance Abuse
Goldberg, J. F. (2007)
Grunze, H., Heinrich, T. W., & Walden, J. (2018) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-018-2062-y
Bipolar disorder co-morbid with addictions
Goikolea, J. M., & Vieta, E. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511776922.013
Antipsicóticos de larga duración en patología dual: evolución de 5 años
Millares, M. V., Salgado-Santamaría, S., Vicente-Alba, J., Gago-Ageitos, A. M., García-Mahía, M. D. C., & Carrera-Machado, I. (2024) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2024.04.007
Bipolar Affective Disorders and Alcohol Dependence: Comorbidity, Consequences, and Treatment
Preuss, U. W., Wong, J. W. M., & Farren, C. K. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_9
Metadata
- Authors
- Brown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Brown, E. Sherwood
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-06-15
- Volume
- 66
- Issue
- 06
- Pages
- 756-760
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2004252407
- Cited by
- 118
- References
- 0
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 2 · 2021: 5 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- aripiprazole, bipolar disorder, schizoaffective disorder, substance abuse, dual diagnosis, antipsychotic switching, alcohol craving, cocaine craving, alcoholism, cocaine dependence, mania, depression, antipsychotic adverse effects, akathisia
- MeSH terms
- Aripiprazole, Adult, Ambulatory Care, Bipolar Disorder, Female, Humans, Male, Pilot Projects, Piperazines, Psychiatric Status Rating Scales, Psychotic Disorders, Antipsychotic Agents, Quinolones, Comorbidity, Treatment Outcome, Receptors, Dopamine D2, Diagnosis, Dual (Psychiatry), Dopamine Agonists, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.